DE10112882A1 - Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren - Google Patents
Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden TumorenInfo
- Publication number
- DE10112882A1 DE10112882A1 DE10112882A DE10112882A DE10112882A1 DE 10112882 A1 DE10112882 A1 DE 10112882A1 DE 10112882 A DE10112882 A DE 10112882A DE 10112882 A DE10112882 A DE 10112882A DE 10112882 A1 DE10112882 A1 DE 10112882A1
- Authority
- DE
- Germany
- Prior art keywords
- tryptophan
- serotonin
- derivatives
- producing
- htp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 229940076279 serotonin Drugs 0.000 title claims abstract description 28
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 13
- 239000000824 cytostatic agent Substances 0.000 title claims abstract description 11
- 230000001085 cytostatic effect Effects 0.000 title claims abstract description 9
- VQSRKJZICBNQJG-UHFFFAOYSA-N 7-hydroxytryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1O VQSRKJZICBNQJG-UHFFFAOYSA-N 0.000 title claims description 17
- 210000004881 tumor cell Anatomy 0.000 title claims description 9
- 239000003053 toxin Substances 0.000 title claims description 7
- 231100000765 toxin Toxicity 0.000 title claims description 7
- 108700012359 toxins Proteins 0.000 title claims description 7
- 231100000252 nontoxic Toxicity 0.000 title description 2
- 230000003000 nontoxic effect Effects 0.000 title description 2
- -1 7-hydroxytryptophan Chemical class 0.000 title 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 claims description 16
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 12
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 claims description 9
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 claims description 9
- LXWHQTNFZDTKBH-UHFFFAOYSA-N 5,7-dihydroxytryptamine Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1O LXWHQTNFZDTKBH-UHFFFAOYSA-N 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 4
- 208000006971 mastocytoma Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- NXANGIZFHQQBCC-VIFPVBQESA-N (2s)-2-amino-3-(6-hydroxy-1h-indol-3-yl)propanoic acid Chemical compound OC1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 NXANGIZFHQQBCC-VIFPVBQESA-N 0.000 claims description 3
- QSHLMQDRPXXYEE-UHFFFAOYSA-N 6-Hydroxytryptophan Natural products C1=CC(O)=C2C(CC(N)C(O)=O)=CNC2=C1 QSHLMQDRPXXYEE-UHFFFAOYSA-N 0.000 claims description 3
- NXANGIZFHQQBCC-UHFFFAOYSA-N DL-6-Hydroxy-tryptophan Natural products OC1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 NXANGIZFHQQBCC-UHFFFAOYSA-N 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 208000037841 lung tumor Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- SKOKLDQYOKPCPU-UHFFFAOYSA-N 3-(2-aminoethyl)-1h-indole-5,6-diol Chemical compound OC1=C(O)C=C2C(CCN)=CNC2=C1 SKOKLDQYOKPCPU-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000012050 conventional carrier Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- QSHLMQDRPXXYEE-ZETCQYMHSA-N 4-hydroxy-L-tryptophan Chemical compound C1=CC(O)=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QSHLMQDRPXXYEE-ZETCQYMHSA-N 0.000 claims 1
- 230000006957 competitive inhibition Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 108010045269 tryptophyltryptophan Proteins 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 2
- 210000001072 colon Anatomy 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 230000003305 autocrine Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- RETCYVKOCFWWTL-UHFFFAOYSA-N 3-(2-aminoethyl)-1h-indol-7-ol Chemical compound C1=CC=C2C(CCN)=CNC2=C1O RETCYVKOCFWWTL-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10112882A DE10112882A1 (de) | 2001-03-15 | 2001-03-15 | Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren |
| PCT/DE2002/000959 WO2002074309A2 (de) | 2001-03-15 | 2002-03-15 | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren |
| US10/471,776 US20040097576A1 (en) | 2001-03-15 | 2002-03-15 | Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors |
| ES02732330T ES2225789T3 (es) | 2001-03-15 | 2002-03-15 | Empleo de derivados de triptofano para el tratamiento citostatico especifico de tumores productores de serotonina. |
| JP2002573016A JP2004519500A (ja) | 2001-03-15 | 2002-03-15 | セロトニン生成腫瘍の特異的細胞増殖抑制性治療に関するトリプトファン誘導体の使用法 |
| EP02732330A EP1368027B1 (de) | 2001-03-15 | 2002-03-15 | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren |
| DE50200757T DE50200757D1 (de) | 2001-03-15 | 2002-03-15 | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren |
| AT02732330T ATE272400T1 (de) | 2001-03-15 | 2002-03-15 | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren |
| US11/847,970 US20070299128A1 (en) | 2001-03-15 | 2007-08-30 | Use of Tryptophan Derivatives for the Specific Cytostatic Treatment of Serotonin-Producing Tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10112882A DE10112882A1 (de) | 2001-03-15 | 2001-03-15 | Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10112882A1 true DE10112882A1 (de) | 2002-09-19 |
Family
ID=7677818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10112882A Withdrawn DE10112882A1 (de) | 2001-03-15 | 2001-03-15 | Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren |
| DE50200757T Expired - Fee Related DE50200757D1 (de) | 2001-03-15 | 2002-03-15 | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50200757T Expired - Fee Related DE50200757D1 (de) | 2001-03-15 | 2002-03-15 | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040097576A1 (https=) |
| EP (1) | EP1368027B1 (https=) |
| JP (1) | JP2004519500A (https=) |
| AT (1) | ATE272400T1 (https=) |
| DE (2) | DE10112882A1 (https=) |
| ES (1) | ES2225789T3 (https=) |
| WO (1) | WO2002074309A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114736149A (zh) * | 2019-03-08 | 2022-07-12 | 哈尔滨商业大学 | 一种2,3-二氢色胺类化合物的合成方法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10043124A1 (de) * | 2000-08-31 | 2002-03-14 | Max Delbrueck Centrum | Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase |
| GB2409048B (en) | 2003-12-09 | 2007-07-11 | Peter Steven Robertson | Electricity metering |
| US20060264178A1 (en) * | 2005-05-20 | 2006-11-23 | Noble Gayle L | Wireless diagnostic systems |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2236876C3 (de) * | 1971-08-19 | 1981-02-12 | Ajinomoto Co., Inc., Tokio | N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel |
| US4183858A (en) * | 1977-07-01 | 1980-01-15 | Merrell Toraude Et Compagnie | α-Vinyl tryptophanes |
| DE3519687A1 (de) * | 1985-06-01 | 1986-12-04 | Veit Arend | Aminosaeuren enthaltendes arzneimittel |
| US5631281A (en) * | 1989-06-29 | 1997-05-20 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives |
| US6124263A (en) * | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| WO2003030907A1 (en) * | 2001-10-09 | 2003-04-17 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
-
2001
- 2001-03-15 DE DE10112882A patent/DE10112882A1/de not_active Withdrawn
-
2002
- 2002-03-15 JP JP2002573016A patent/JP2004519500A/ja not_active Withdrawn
- 2002-03-15 EP EP02732330A patent/EP1368027B1/de not_active Expired - Lifetime
- 2002-03-15 US US10/471,776 patent/US20040097576A1/en not_active Abandoned
- 2002-03-15 DE DE50200757T patent/DE50200757D1/de not_active Expired - Fee Related
- 2002-03-15 ES ES02732330T patent/ES2225789T3/es not_active Expired - Lifetime
- 2002-03-15 AT AT02732330T patent/ATE272400T1/de not_active IP Right Cessation
- 2002-03-15 WO PCT/DE2002/000959 patent/WO2002074309A2/de not_active Ceased
-
2007
- 2007-08-30 US US11/847,970 patent/US20070299128A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114736149A (zh) * | 2019-03-08 | 2022-07-12 | 哈尔滨商业大学 | 一种2,3-二氢色胺类化合物的合成方法 |
| CN114736149B (zh) * | 2019-03-08 | 2023-04-18 | 哈尔滨商业大学 | 一种2,3-二氢色胺类化合物的合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE50200757D1 (de) | 2004-09-09 |
| ATE272400T1 (de) | 2004-08-15 |
| ES2225789T3 (es) | 2005-03-16 |
| US20070299128A1 (en) | 2007-12-27 |
| WO2002074309A2 (de) | 2002-09-26 |
| US20040097576A1 (en) | 2004-05-20 |
| EP1368027B1 (de) | 2004-08-04 |
| JP2004519500A (ja) | 2004-07-02 |
| EP1368027A2 (de) | 2003-12-10 |
| WO2002074309A3 (de) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2106172C (en) | Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the treatment of restenosis associated with coronary intervention | |
| Bencini et al. | Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients | |
| Rephaeli et al. | Derivatives of butyric acid as potential anti‐neoplastic agents | |
| DE60003010T2 (de) | Verwendung eines serenoa repens extraktes zur herstellung eines arzneimittels zur behandlung von krebserkrankungen der prostata | |
| JP2008110996A (ja) | 体脂肪低減用組成物 | |
| DE102006026464A1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus | |
| JPH02215719A (ja) | 線維化病変組織の修復並びに線維化病変の阻止剤 | |
| CN1073843C (zh) | 熊果酸或其盐在制备抑制转移的药物中的应用 | |
| Grimaitre et al. | Topical colchicine therapy for actinic keratoses | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| DE60030842T2 (de) | VERWENDUNG VON ZUSAMMENSETZUNGEN ENTHALTEND CldC ALS STRAHLUNGSSENSIBILISATOREN IN DER BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN | |
| DE69413090T2 (de) | Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel | |
| EP1368027B1 (de) | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren | |
| JPS631287B2 (https=) | ||
| Moore et al. | The porphyrias | |
| Murakami et al. | TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span | |
| JP2001322990A (ja) | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 | |
| DE68908404T2 (de) | Lang haltende zusammensetzung von propafenon und chinidin zur behandlung des zustandes des herzens. | |
| Roemeling et al. | Lack of antiemetic effect of high-dose metoclopramide. | |
| EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
| US10568907B1 (en) | Methods of treating basal cell carcinoma and glioblastoma | |
| Spath et al. | Diethyldithiocarbamate inhibits scheduled and unscheduled DNA synthesis of rat thymocytes in vitro and in vivo—dose-effect relationships and mechanisms of action | |
| JPH05509291A (ja) | フェニルアミン系脱色素、抗黒色腫剤 | |
| DE69900336T2 (de) | Pentoxifyllin und antizytokin enthaltende pharmazeutische zusammensetzungen | |
| KR100854873B1 (ko) | 세포 증식 억제제의 세포 고사 효과를 강화하는 5-치환뉴클레오시드의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |